MRNIP is a replication fork protection factor.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
07 2020
Historique:
received: 16 12 2019
accepted: 28 05 2020
entrez: 25 8 2020
pubmed: 25 8 2020
medline: 25 8 2020
Statut: epublish

Résumé

The remodeling of stalled replication forks to form four-way DNA junctions is an important component of the replication stress response. Nascent DNA at the regressed arms of these reversed forks is protected by RAD51 and the tumor suppressors BRCA1/2, and when this function is compromised, stalled forks undergo pathological MRE11-dependent degradation, leading to chromosomal instability. However, the mechanisms regulating MRE11 functions at reversed forks are currently unclear. Here, we identify the MRE11-binding protein MRNIP as a novel fork protection factor that directly binds to MRE11 and specifically represses its exonuclease activity. The loss of MRNIP results in impaired replication fork progression, MRE11 exonuclease-dependent degradation of reversed forks, persistence of underreplicated genomic regions, chemosensitivity, and chromosome instability. Our findings identify MRNIP as a novel regulator of MRE11 at reversed forks and provide evidence that regulation of specific MRE11 nuclease activities ensures protection of nascent DNA and thereby genome integrity.

Identifiants

pubmed: 32832601
doi: 10.1126/sciadv.aba5974
pii: aba5974
pmc: PMC7439443
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eaba5974

Subventions

Organisme : Cancer Research UK
ID : 12102
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Références

EMBO Rep. 2018 Sep;19(9):
pubmed: 30104203
Genes Dev. 2017 Jul 15;31(14):1469-1482
pubmed: 28860160
Nat Commun. 2015 Aug 19;6:8088
pubmed: 26286827
Nature. 2019 Jul;571(7766):521-527
pubmed: 31270457
Mol Biol Cell. 2008 Apr;19(4):1693-705
pubmed: 18256278
Nucleic Acids Res. 2015 Nov 16;43(20):9788-803
pubmed: 26275776
Methods Mol Biol. 2018;1672:261-294
pubmed: 29043630
J Cell Biol. 2015 Mar 2;208(5):563-79
pubmed: 25733714
Genes Cells. 2015 Dec;20(12):1059-76
pubmed: 26525166
Cell Rep. 2016 Sep 6;16(10):2565-2575
pubmed: 27568553
Nat Commun. 2017 Oct 16;8(1):859
pubmed: 29038466
Biomed Res Int. 2013;2013:747318
pubmed: 23586058
Nature. 2016 Jul 20;535(7612):382-7
pubmed: 27443740
Mol Cell. 2018 Nov 1;72(3):568-582.e6
pubmed: 30344097
EMBO J. 2009 Sep 2;28(17):2601-15
pubmed: 19629035
Cell Rep. 2018 Jul 17;24(3):538-545
pubmed: 30021152
Mol Cell. 2015 Aug 6;59(3):462-77
pubmed: 26166705
Nature. 2014 Oct 2;514(7520):122-5
pubmed: 25231868
Nature. 2011 Oct 16;479(7372):241-4
pubmed: 22002605
Mol Cell. 2016 Dec 1;64(5):940-950
pubmed: 27889449
EMBO Rep. 2018 Jul;19(7):
pubmed: 29739811
FEBS Lett. 2017 Apr;591(8):1083-1100
pubmed: 28079255
Mol Cell. 2017 Sep 7;67(5):867-881.e7
pubmed: 28757209
Mol Cell. 2017 Aug 3;67(3):374-386.e5
pubmed: 28735897
Nat Commun. 2017 Oct 16;8(1):860
pubmed: 29038425
Mol Cell Biol. 1997 Apr;17(4):2136-42
pubmed: 9121462
Endocr Relat Cancer. 2016 Oct;23(10):T1-T17
pubmed: 27530658
Methods Enzymol. 2018;600:25-66
pubmed: 29458761
Cell Rep. 2019 May 28;27(9):2558-2566.e4
pubmed: 31141682
Genes Dev. 2011 Jun 15;25(12):1320-7
pubmed: 21685366
J Biol Chem. 2013 Nov 1;288(44):31458-67
pubmed: 24047897
Nat Protoc. 2012 Mar 01;7(3):594-605
pubmed: 22383038
Nat Med. 2018 Jul;24(7):927-930
pubmed: 29892067
Nucleic Acids Res. 2015 Sep 30;43(17):8352-67
pubmed: 26240375
Nature. 2008 Jan 3;451(7174):81-5
pubmed: 18172500
Cell. 2011 May 13;145(4):529-42
pubmed: 21565612
J Cell Biol. 2015 Mar 2;208(5):545-62
pubmed: 25733713
J Biol Chem. 2006 Oct 13;281(41):30814-23
pubmed: 16905549
Nat Cell Biol. 2014 Jan;16(1):2-9
pubmed: 24366029
Cell Rep. 2014 Jan 16;6(1):182-95
pubmed: 24388752
Mol Cell. 2017 Oct 19;68(2):414-430.e8
pubmed: 29053959

Auteurs

L G Bennett (LG)

North West Cancer Research Institute, School of Medical Sciences, Bangor University, Bangor LL57 2UW, UK.

A M Wilkie (AM)

North West Cancer Research Institute, School of Medical Sciences, Bangor University, Bangor LL57 2UW, UK.

E Antonopoulou (E)

North West Cancer Research Institute, School of Medical Sciences, Bangor University, Bangor LL57 2UW, UK.

I Ceppi (I)

Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Institute of Biochemistry, Department of Biology, ETH Zürich, 8093 Zürich, Switzerland.

A Sanchez (A)

Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.

E G Vernon (EG)

North West Cancer Research Institute, School of Medical Sciences, Bangor University, Bangor LL57 2UW, UK.

A Gamble (A)

North West Cancer Research Institute, School of Medical Sciences, Bangor University, Bangor LL57 2UW, UK.

K N Myers (KN)

Sheffield Institute for Nucleic Acids, Department of Oncology and Metabolism, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK.

S J Collis (SJ)

Sheffield Institute for Nucleic Acids, Department of Oncology and Metabolism, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK.

P Cejka (P)

Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Institute of Biochemistry, Department of Biology, ETH Zürich, 8093 Zürich, Switzerland.

C J Staples (CJ)

North West Cancer Research Institute, School of Medical Sciences, Bangor University, Bangor LL57 2UW, UK.

Classifications MeSH